MetaCap

ADMA Biologics (ADMA) vs CRISPR Therapeutics (CRSP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CRISPR Therapeutics (CRSP) has outperformed ADMA Biologics (ADMA) over the past year, losing 22.2% versus a loss of 23.3%. Over five years, ADMA leads with a +808.3% price change compared with -50.4% for CRSP. CRISPR Therapeutics is the larger company by market cap ($3.79 billion vs $2.92 billion), about 1.3 times the size, while ADMA Biologics is growing revenue faster (+19.6% vs -90.6%).

ADMA Biologics converts more of its revenue into profit, with a net margin of 28.8% versus -16569.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADMA-23.34%CRSP-22.16%
+27%-16%-60%
Nov 21, 20251 yearNov 20, 2026
ADMA+760.78%CRSP-52.57%
+1512%+688%-135%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADMA versus CRSP key metrics
MetricADMACRSP
Share price$13.17$39.10
Market cap$2.92B$3.79B
1-day change-1.27%+0.44%
YTD return-27.80%-25.44%
1-year return-23.34%-22.16%
5-year return+808.28%-50.37%
P/E ratio (TTM)17.10—
Forward P/E14.06—
EPS (TTM)$0.77$-4.73
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$510.17M$3.51M
Revenue growth (YoY)+19.63%-90.59%
Net income (latest FY)$146.93M$-581.60M
Gross margin57.39%—
Operating margin37.53%-18933.65%
Net margin28.80%-16569.77%
52-week high$20.46$63.45
52-week low$7.21$38.15
Distance from 52-week high-35.62%-38.38%
Analyst consensusbuybuy
Avg. price target upside+36.67%+118.47%
Average volume3.23M1.74M
Shares outstanding221.85M97.00M
Employees640—
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ADMA Biologics is more profitable, keeping 28.8 cents of every revenue dollar as net income versus -16569.8 cents for CRISPR Therapeutics.
  • ADMA Biologics grew revenue faster in its latest fiscal year (+19.63% vs -90.59%).

About ADMA Biologics

ADMA stock →

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees

About CRISPR Therapeutics

CRSP stock →

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

ADMA vs CRSP FAQ

Which is bigger, ADMA Biologics or CRISPR Therapeutics?

CRISPR Therapeutics (CRSP) is larger, with a market capitalization of $3.79B compared with $2.92B for ADMA Biologics (ADMA).

Which stock has performed better over the past year, ADMA or CRSP?

CRSP returned -22.16% over the past 12 months, compared with -23.34% for ADMA (price return, excluding dividends). Past performance does not predict future results.

Are ADMA Biologics and CRISPR Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons